Literature DB >> 717282

Endometrial lesions in uteri resected for atypical endometrial hyperplasia.

F Tavassoli, F T Kraus.   

Abstract

Resected uteri from a series of 48 consecutive patients with atypical endometrial hyperplasia ("carcinoma in situ") identified in curettings were studied to determine the frequency of associated adenocarcinoma. Thirty-nine of the women had received estrogen or oral contraceptives. Twelve uteri (25%) contained small superficial foci interpreted as well differentiated adenocarcinoma. Consideration of this observation together with the absence of adenocarcinoma in the extensive experience reported in other studies of women with atypical hyperplasia treated with progestogens alone shows a deficit of patients with progression to invasive carcinoma. We reconcile this apparent conflict with the hypothesis that lesions classified as focal well-differentiated endometrial adenocarcinoma occurring with atypical hyperplasia in perimenopausal women exposed to estrogen are common and are consistently reversed by progestogen therapy.

Entities:  

Mesh:

Year:  1978        PMID: 717282     DOI: 10.1093/ajcp/70.5.770

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

3.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

4.  [Myometrium and endometrium. Histopathologic aspects of benign lesions].

Authors:  C Y Genton
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

Review 5.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

6.  Diagnosing endometrial hyperplasia: why is it so difficult to agree?

Authors:  Kimberly H Allison; Susan D Reed; Lynda F Voigt; Carolyn D Jordan; Kathryn M Newton; Rochelle L Garcia
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

7.  A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers.

Authors:  G L Mutter; M L Chaponot; J A Fletcher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 8.  Upper genital tract abnormalities in the Syrian hamster as a result of in utero exposure to diethylstilbestrol. I. Uterine cystadenomatous papilloma and hypoplasia.

Authors:  J Gilloteaux; R J Paul; A W Steggles
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1982

9.  Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia.

Authors:  Kurt Christopher Giede; Tin-Wing Yen; Rajni Chibbar; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2008-10

Review 10.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.